



हरियाणा HARYANA

AA 257482

SUPPLY CONTRACT

This **SUPPLY AGREEMENT** is made and executed on April 7th, 2025.

HEALTH WORLD CASA DE REPRESENTACIONES, C.A Registro de Information Fiscal N. J501664374, a company organized and existing under the laws of Venezuela, principal address. Venezuela, Caracas, Distrito Capital, Avenida Lecuna, Cipreces al Hoyo. Edificio Centro Empresarial Cipreces, Piso 4, Oficina C, Urbanizacion Santa Rosalia, represented herein by **JHONATAN JHOSSUE SIMOES MORENO**. Passport number 171131996.

ARVINCARE having Registered office at M/S ARVINCARE SCO-62 FIRST FLOOR SECTOR-12A PANCHKULA (HR) INDIA. We hereby have manufacturing units mentioned below.

1. **Salus Pharmaceuticals** 480/211 Village Harraipur Nalagarh road Baddi (HP) 173205
2. **Sunvet Healthcare**, Village Shambhuwala Paonta Road Tehsil Nahan Dist. Nalagarh (HP)

a company incorporated in India hereinafter referred to as which expression shall include its successors, representatives, assigns including contract manufacturing partners and associated companies of the First Part y. Executive Director – **Abhinav Garg**, Passport Number – **W0862718**

WHEREAS

ARVINCARE is a company in India and is engaged in the business of Manufacturing, Trade & Export of pharmaceuticals and medicinal products for human and animal use.

HEALTH WORLD CASA DE REPRESENTACIONES, C.A is dedicated to the manufacture, import and distribution of medicines, medical supplies, raw materials, medical equipment and production equipment.



07 APR 2025






M/s Arvind / Sec 62 & 12 A

Venckels tr.

Asiok Kumar
E Stamp Vendor
Reg. No. RA/HR/08
MSD. No. 001913355

399
07/04/2025



HEALTH WORLD CASA DE REPRESENTACIONES, C.A and ARVINCARE by means of the present contract for the production, distribution and supply of pharmaceutical products, raw materials and equipment for the production, as well as the support in technology transfer, licenses and patents for the production to the Ministry of Health or any other governmental or private agency of the Republic of Venezuela.

THE PRESENT AGREEMENT ESTABLISHES THE FOLLOWING.

1. DEFINITIONS:

1. The expression "PRODUCT" means formulations agreed by the parties as per ANNEX I to be manufactured by ARVINCARE and sold to HEALTH WORLD CASA DE REPRESENTACIONES, C.A for supply requested by the Venezuelan State represented by the Ministry of People's Power for Health and private companies in Venezuela.
2. "CONFIDENTIALITY" shall mean and include all information relating to proprietary information that may be disclosed by one party to the other in connection with the "PRODUCT" or any other know-how, product, technology, marketing and business strategies of the disclosing party.
3. The expression "INTELLECTUAL PROPERTY RIGHTS" shall mean and include all rights, interests vested in or relating to or arising from any patents, technology, trade secrets, goodwill or "CONFIDENTIAL INFORMATION", whether arising by common law or by statute.

2. PROVISIONS:

1. ARVIN CARE agrees to manufacture, sell and deliver the Product/s as per ANNEX I to HEALTH WORLD CASA DE REPRESENTACIONES, C.A under the terms of this Agreement and HEALTH WORLD CASA DE REPRESENTACIONES, C.A for its part agrees to purchase the PRODUCT/s from ARVINCARE for its commercialization in the Venezuelan State represented by the Ministry of People's Power for Health and to other private companies.
2. HEALTH WORLD CASA DE REPRESENTACIONES, C.A will market the products to the Venezuelan State represented by the Ministry of People's Power for Health and private companies and ARVINCARE will not manufacture or supply such products to any other party in the Venezuelan territory.
3. ARVINCARE undertakes to provide the relevant legal documentations in accordance with the regulatory requirement of both India and Venezuela, within 31 days of signing this agreement.
4. In the event that ARVINCARE fails to provide the required materials within 30 days of signing the contract, HEALTH WORLD CASA DE REPRESENTACIONES, C.A has the right to terminate the contract and have ARVINCARE reimburse HEALTH WORLD CASA DE REPRESENTACIONES, C.A for the costs incurred in legalizing the product and a 10% penalty plus administrative costs.
5. ARVINCARE will also inform and provide all necessary documents to comply with any new specifications or mutually agreed modifications required by the Venezuelan State Health Authorities within a period of no more than 30 to 60 days.

14 MAY 2025

INDO LATAMERICAN CHAMBER OF COMMERCE
NEW DELHI, INDIA

GOVT


Tomar
cate
Delhi
No.
3

6. Above supply of documents **THE LABORATORY** undertakes to deliver to the person designated by **THE REPRESENTATIVE HOUSE** all the information and documentation required for the product registration process with the Venezuelan health authority, as stipulated in **ANNEX I**
7. **THE LABORATORY** acknowledges and accepts that the ownership of the drug formula and its development belong to **THE REPRESENTATIVE HOUSE**, and also expressly waives and right over it, as indicated in an **APPENDIX I**. Likewise, **THE LABORATORY** undertakes to collaborate in the regulatory and administrative process necessary for the registration and certification of the products in the Bolivarian Republic of Venezuela.
8. Legal filing fees and other registration expenses incurred in the registration process, including the cost of official registration and other registration expenses in Venezuela will be by **HEALTH WORLD CASA DE REPRESENTACIONES, C.A**
9. Above supply of Samples for registration **THE LABORATORY** undertakes to provide the number of samples necessary for the product registration process with the Venezuela health authority, as stipulated in current Venezuela regulations, and undertakes cover all shipping and logistics costs that this process generates.
10. Above supply of Samples for Batch Certification: **THE LABORATORY** undertakes to deliver the number of samples required by the Venezuelan health authority for the batch certification of the products, in accordance with the legislation applicable in Venezuelan territory, and undertakes to cover all shipping and logistics costs for all samples it provides for the proper continuity of the process.
11. The addition or deletion of the list of products in the **ANNEX I** will be made only after mutual agreement between **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** and **ARVINCARE** through an **ADENDU**.
12. **ARVINCARE** warrants that all documentation, samples and related substances are original, authentic and duly certified by the relevant authorities in India. If any material provided by **ARVINCARE** is proven to be false, **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** shall be entitled to be indemnified by **ARVINCARE** for damages with a monetary value equivalent to 100% of its profits for that period.

3. **SALES ESTIMATES:**

1. **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** agrees to provide **ARVINCARE** with an annual forecast prior to the commencement of sales to facilitate **ARVINCARE** to carry out production planning of the **PRODUCTS** for sale and supply under the terms of this **AGREEMENT**.

4. **SUPPLY, PRICE AND PAYMENT:**



1. **ARVINCARE** undertakes to sell and supply the **PRODUCT(s)** to **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** at mutually agreed prices. The prices shall be fixed for a minimum of five years and shall be mutually reviewed after two years.
2. If **ARVINCARE** incurs a sharp increase during the two years in statutory taxes or new taxes are imposed, a major change in raw material prices and operating costs of 5% or more, valid documentary proof must be submitted to **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** at least 120 days before the price changes take effect.
3. In case **ARVINCARE** cannot justify with original documentary evidence the price increase of more than 5% with any of the above-mentioned reasons, it shall maintain the originally agreed prices.
4. If **ARVINCARE** does not justify with original documentary evidence the price increase and does not continue supplying at the agreed prices within 30 days after the purchase order, **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** will have the right to terminate the contract and claim from **ARVINCARE** a compensation of a monetary value equal to the performance bond and any other fine that **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** imposed on the contracting Venezuelan State, equivalent to 30% of the sales volume of the contract.
5. The reference price would be the price quoted at the time of quotation of the purchase and not the price quoted at the time of selection of the product for registration. Any price increase at the time of quotation shall be subject to the parameters set forth in this clause 4.1.
6. The sale of the Product from **ARVINCARE** to **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** shall be on a cash basis and title and risk of loss for all shipments shall pass to **HEALTH WORLD CASA DE REPRESENTACIONES, C.A**, with delivery to the port of origin to be agreed upon by both parties.
7. The terms, including the price of the product, will be stated in the Purchase Order placed by **HEALTH WORLD CASA DE REPRESENTACIONES, C.A**. The terms and conditions stated in the Purchase Order shall not be modified or changed without the prior written consent of **HEALTH WORLD CASA DE REPRESENTACIONES, C.A**. Periodic delivery instructions indicating the quantities required and delivery dates shall be communicated to **ARVINCARE** by **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** at least six weeks prior to the agreed delivery date.
8. Payments will be made through **HEALTH WORLD CASA DE REPRESENTACIONES, C.A**, 50% down payment together with the Purchase Order and balance 50% of the amount at the time of shipment against commercial invoice, packing list and delivery to the customs broker selected for the shipping operation at the Port of destination. We do not rule out

14 MAY 2025



NEW DELHI, INDIA

the opening of credit lines or payments upon arrival of the merchandise to Venezuela, or as mutually agreed.

9. Payments will be made directly to the manufacturing laboratory headquartered in India or to another company agreed between the parties, either in India or another country agreed between the parties.
10. Payments will be made in USD, Euros, Rupees or any other currency agreed between the parties, always by direct bank transfer.
11. The execution of Bank Guarantees is agreed upon as a method of insurance of the parties in the event that any of the parties should request it.

5. QUALITY AND SPECIFICATIONS:

1. **ARVINCARE** warrants that the production, distribution and supply of the **PRODUCT /S** of superior quality manufactured and packaged in accordance with the relevant country standards/norms as specified by the relevant regulatory authorities in the Venezuelan State, as applicable.
2. **ARVINCARE** warrants that the **PRODUCT(s)** shall have a shelf life of not less than 80% of the useful life from the date of manufacture and delivery of the product(s) to Venezuela at the time of dispatch. **ARVINCARE**, at its own expense, while the product is in its possession, shall keep the same properly insured.
3. **ARVINCARE** shall ensure that the **PRODUCT** is stored in suitable conditions to ensure its quality, efficacy, safety and marketability at all times, while in its possession or under its control. **ARVINCARE** will allow **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** to engage third parties to inspect the shipment prior to export to ensure that the packaging is adequate and arrives in good condition.
4. **ARVINCARE** will obtain and maintain the necessary regulatory approvals of its manufacturing facilities (including packaging facilities) for the **PRODUCTS** from the relevant regulatory agency in the country of origin, prior to delivery of the products to **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** and warrants that the manufacturing facilities will continue to comply with the sanctioning terms of the regulatory agency including Good Manufacturing Practice standards during the term of this agreement.
5. **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** shall have the right to ensure that the **PRODUCTS** and/or Samples received comply with the final quality specifications upon receipt of the **PRODUCT/Samples** from **ARVINCARE** in the event **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** or the **TERRITORY Health Authority** determines that the specified **PRODUCT** does not meet the agreed quality specifications **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** shall notify **ARVINCARE** no later than 10 working days of the discrepancies found. If **ARVINCARE** does not agree with such findings notified by



HEALTH WORLD CASA DE REPRESENTACIONES, C.A, samples of the product will be sent to Official Quality Control Laboratory of HEALTH WORLD CASA DE REPRESENTACIONES, C.A, for analysis of the PRODUCT(s). The results of such tests shall be final, and the cost of such tests shall be borne by the losing party.



6. Notwithstanding the foregoing, ARVINCARE shall be solely responsible for all defects in workmanship and/or quality of the products it supplies to HEALTH WORLD CASA DE REPRESENTACIONES, C.A, if such defects originate at the point of delivery, and ARVINCARE shall not be liable for physical or quality damage that may occur during transportation or storage under improper conditions of such PRODUCTS at HEALTH WORLD CASA DE REPRESENTACIONES, C.A premises.
7. ARVINCARE agrees to inspection of its facilities/works and other locations where the related project is carried out by HEALTH WORLD CASA DE REPRESENTACIONES, C.A personnel for validation of the manufacturing process and standards/issues related to quality control and/or quality assurance of the product(s) prior to commencement of supplies by ARVINCARE and periodically under this AGREEMENT.
8. Suggestions/modifications by HEALTH WORLD CASA DE REPRESENTACIONES, C. Ain this regard shall be implemented/performed by ARVINCARE to the satisfaction of HEALTH WORLD CASA DE REPRESENTACIONES, C.A, if feasible and/or required by WHO and the regulatory health authority in the Venezuelan State.

6. **PRODUCT PACKAGING:**

1. It is hereby agreed that the packaging material of the PRODUCT /S, including package inserts and labels, shall be manufactured and supplied by ARVINCARE to HEALTH WORLD CASA DE REPRESENTACIONES, C.A, and shall include such texts, color scheme, design scheme and languages approved by the regulatory authority in the Venezuelan State.

REMEMBER

1. If HEALTH WORLD CASA DE REPRESENTACIONES, C.A or a regulatory authority of the Venezuelan State orders a voluntary or mandatory recall for any reason other than product manufacturing, packaging, expiration date, adverse effects, or any other reason related to the product, HEALTH WORLD CASA DE REPRESENTACIONES, C.A will promptly manage the recall, and ARVINCARE will cooperate and assist HEALTH WORLD CASA DE REPRESENTACIONES, C.A in the recall. The cost of such recall will be agreed upon by the parties. If the reason for the recall is due to a product-related issue, ARVINCARE will manage and implement the recall and cover the costs involved.





2. **ARVINCARE** will annually submit a periodic safety report on adverse reactions, safety update regarding global drug safety experience, which will be submitted to the Venezuelan State Health Authorities.

8. PHARMACOVIGILANCE

1. During the Term, each Party shall report to the other Party any actual or suspected Adverse Reaction Information with respect to the Product and/or any Additional Product of which it becomes aware immediately upon initial receipt of the information by such Party; provided, however, that neither Party shall be obligated to report such information to the other Party prior to the time at which, or in other than the form in which, such information is required to be reported.
2. For purposes of this **AGREEMENT**, "Adverse Reaction Information" includes, but is not limited to, information regarding any experience with respect to the Product and/or any additional Product in the **TERRITORY** that:

- (a) suggests a significant hazard, contraindication, side effect or precaution not identified in the labeling of the Product and/or any Additional Product,
 - a) is fatal or life-threatening,
 - b) is permanently disabling,
 - c) requires or prolongs the patient's hospitalization,
 - d) involves a congenital abnormality or
 - e) is adverse and is not identified in nature, specificity, severity or frequency in the labeling of the Product and/or any Additional Product.
- Prior to the First Commercial Sale of the Licensed Product in the **TERRITORY**, the Parties shall comply with pharmacovigilance requirements which shall include, among other things, mutually acceptable guidelines and procedures for the receipt, investigation, reporting and exchange (between the Parties) of safety information, such as adverse events, lack of efficacy, misuse/abuse and any other information relating to the safety of the Licensed Product. Such guidelines and procedures shall be in accordance with and enable the Parties to comply with regulatory reporting obligations to Regulatory Authorities.
- In addition, such agreed procedures shall be consistent with relevant Regulatory Authority and International Conference on Harmonization (ICH) guidelines, except where such guidelines may conflict with existing more stringent local regulatory safety reporting requirements, in which case the local reporting requirements shall prevail.



9. **WARRANTIES AND LIABILITY:**



1. The products supplied under this Agreement have been manufactured using good manufacturing practices and in accordance with the specifications approved by the respective Ministry of Health in the **TERRITORY**.

LIABILITY OF ARVINCARE

- A direct loss or damage to **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** (excluding loss of profit and reputation) sufficiently demonstrated to be the result of any defect or failure in the quality or condition of the Product, where the Products do not comply with the Specifications provided that the defect or failure does not result from the conditions in which the Products have been stored or transported after the Products were first delivered to **HEALTH WORLD CASA DE REPRESENTACIONES, C.A**, shall be indemnified by **ARVINCARE**, provided that such claim shall be notified to **ARVINCARE** as soon as practicable but in any event not later than 60 days from the date of notification of non-compliance by **ARVINCARE** by the regulatory authority or receipt of the claim from any third party. Such notice must contain details of the basis of the claim, to the extent possible, proof that the basis of the claim is the direct result of the defect or failure in the quality or condition of the Products and that conditions in storage or transportation after the Products were first delivered to Distributor did not contribute to the basis of the claim.

LABORATORY OBLIGATIONS

1. **Supply of Documentation:** **ARVINCARE** undertakes to deliver to the person designated by **HEALTH WORLD CASA DE REPRESENTACIONES, C.A** all the information and documentation required for the product registration process with the Venezuelan health authority, as stipulated in Annex I.
2. **Adaptation of Documents:** **ARVINCARE** undertakes to make the necessary modifications to the documentation, within the legal and moral framework, according to the indications of **HEALTH WORLD CASA DE REPRESENTACIONES, C.A**, in order to adjust it to the requirements established by the health authority in Venezuela, within a period of no more than Fifteen 15 continuous days.
3. **Supply of Samples for Registration:** **ARVINCARE** undertakes to provide the number of samples necessary for the product registration process with the Venezuelan health authority, as stipulated in current Venezuelan regulations, and undertakes to bear all shipping and logistics costs that this process generates.






- d. Independently developed by its employees without access to the other party's information.
3. Each party shall be restricted from using any CONFIDENTIAL INFORMATION required to be kept confidential for any purpose other than the performance of its obligations under this agreement.
4. Each party shall restrict access to CONFIDENTIAL INFORMATION received from the other party to the minimum number of employees necessary for the performance of its obligations under this agreement and shall use the same standard of care to preserve and safeguard the confidential nature of the information disclosed by the other party as is used with its own information of a similar type and shall use its best efforts to ensure that the persons concerned keep such information confidential and comply with this clause.
5. These agreements shall survive the termination of this agreement and the suspension of any obligations under this agreement pursuant to the terms set forth herein.

11. PARTICIPATION IN BIDDING:


1. ARVINCARE shall provide the price to HEALTH WORLD CASA DE REPRESENTACIONES, C.A for each product offer as mutually agreed between the parties at the amount of the offer quotation after registration of the product.
2. The Bid Security for the tender will be arranged by HEALTH WORLD CASA DE REPRESENTACIONES, C.A. ARVINCARE shall adhere to the quotation price of the tender till the validity of the bid security submitted against participation in the particular tender.
3. The performance security for the tender shall be given by HEALTH WORLD CASA DE REPRESENTACIONES, C.A. ARVINCARE shall adhere to the quoted price of the tender until the validity of the performance security submitted against participation in the particular tender.
4. Upon confirmation of the award, ARVINCARE undertake the production, distribution and supply of pharmaceuticals, raw materials and equipment for production, as well as support in technology transfer, licensing and patents for production to HEALTH WORLD CASA DE REPRESENTACIONES, C.A as per the bidding conditions.

12. FORCE MAJEURE:

1. It is agreed that any delay or failure by either party to comply with the terms and conditions set forth in this AGREEMENT shall not be treated as a default or breach and shall not give rise to any claim for damages in favor of either party.
2. In the event of any damage, default or failure, caused by events beyond the control of either party, including but not limited to acts of God, fire, flood, explosion, war, civil commotion, strikes, lockouts, legal prohibitions, material and other similar causes.






01 APR 2025



3. The party alleging a force majeure event shall promptly notify the other party in writing and provide full details of the cause or event and the date of its first occurrence. Failure to give such notice to the other party shall deprive the party claiming force majeure from being excused from performing its obligations under this agreement. If the force majeure in question prevails for a continuous period of more than three months, the parties shall enter into good faith discussions with a view to alleviating its effects or agreeing on alternative arrangements that may be fair and reasonable.
4. In the event that no such agreement is agreed, the other party not affected by force majeure shall have the right to terminate this agreement by giving three months' notice to the Party affected by force majeure.
5. This agreement shall enter into force upon execution and shall continue in force for a period of 5 years from the date of registration of the first product. Thereafter, this agreement may be renewed for an additional period of 5 years on mutually agreed terms.
6. Either party shall have the right to terminate the agreement in accordance with clause 16 as provided and agreed between the parties.
7. In addition to any other right of termination provided in this agreement, either party has the right to terminate this agreement by giving 90 days written notice to the other party without stating any reason.
8. Either party shall have the right to terminate the AGREEMENT in the event of default by either party in failing to comply with the stipulation provided herein after giving 15 days' notice to cure such default and if the party has failed to rectify the breach thereof after notice.

13. CONSEQUENCE OF THE TERMINATION:

1. In the event of termination of this agreement, HEALTH WORLD CASA DE REPRESENTACIONES, C.A shall purchase the excess stock of any PRODUCT from ARVINCARE at the purchase price agreed between the parties to the extent that it forms part of the purchase order placed for the period by HEALTH WORLD CASA DE REPRESENTACIONES, C.A
2. In the event of termination by ARVINCARE, if HEALTH WORLD CASA DE REPRESENTACIONES, C.A has any contract pending approval, tender pending award or purchase order in force at the time of termination of the contract, ARVINCARE be responsible for fulfilling and supplying the sale for the duration of the contract. tender in the Venezuelan State.
3. Failure to do so will result in ARVINCARE paying penalties and performance bond to the contracting government agency and will paying too to HEALTH WORLD CASA DE REPRESENTACIONES, C.A a compensation for all administrative expenses incurred by the action taken by the laboratory.



4. Unless otherwise agreed in this AGREEMENT, all obligations created by this AGREEMENT shall cease upon its termination.


14. ARBITRATION:

1. In the event of any dispute, controversy or claim arising out of or relating to this Agreement or the breach, termination or invalidity thereof, the parties shall endeavor to resolve the same amicably in a manner consistent with the spirit of the transaction recorded in this Agreement.
2. However, if the parties are unable to resolve such dispute through the above discussions, the same shall, at the request of either party, be referred to and settled by arbitration in accordance with the Arbitration and Conciliation Act 1996.
3. The place of arbitration shall be according to the international commercial instances. The language to be used in such arbitration proceedings shall be English and Spanish.
4. Any judgment, decision or award of the arbitrators shall be final and binding and shall be enforceable in any court of competent jurisdiction.

15. NOTICE:

All notices under this Agreement shall be sent by registered international courier in English and Spanish to their respective offices as detailed below:

1. M/S ARVINCARE FIRST FLOOR SCO NO-62 SECTOR-12A PANCHKULA (HR)INDIA
- Phone:
 - Contact:
 - E-mail/info.arvincare@gmail.com



2. HEALTH WORLD 'CASA DE REPRESENTACIONES, C.A. Venezuela, Caracas, Distrito Capital, Avenida Lecuna, Cipreces al Hoyo. Edificio Centro Empresarial Cipreces, Piso 4, Oficina C, Urbanizacion Santa Rosalia.

- Contact/JHONATAN JHOSSUE SIMOES MORENO.
- Phone/ +584244346735
- E-mail/ MARIOSIMoes2002@ICLOUD.COM



16. GENERAL:

1. This agreement is on a principal-to-principal basis, neither party being the agent of the other.
2. This agreement does not constitute any partnership or joint venture between the parties.
2. If HEALTH WORLD 'CASA DE REPRESENTACIONES, C.A does not represent a particular therapeutic area or segment, or if HEALTH WORLD 'CASA DE REPRESENTACIONES, C.A is not interested or does not have sufficient resources to market or represent the product(s) in the



TERRITORY or does not meet the sales estimate provided by HEALTH WORLD CASA DE REPRESENTACIONES, C.A where such estimate is reasonable, HEALTH WORLD CASA DE REPRESENTACIONES, C.A will provide bona fide NOC (No Objection Certificate) to ARVINCARE to market its product through any other commercial partner.

3. The failure of either party at any time to enforce any of the terms, provisions or conditions of this Agreement or to exercise any right hereunder shall not constitute a waiver thereof or of the right of the subsequent party to enforce or exercise the same.
4. No modification or amendment of this agreement shall be binding unless agreed to in writing by the Parties.
5. Each party to this agreement acknowledges that this agreement contains the entire agreement between the parties and supersedes any prior agreement/understanding or agreement between the parties hereto.
6. In the event that any provision of this agreement is declared by any judicial or competent authority to be void, voidable, illegal or otherwise unenforceable (or either party receives directions to the same from any relevant competent authority), the parties shall modify such provisions in a reasonable manner so as to achieve the parties' intention without illegality. This agreement shall not be assigned by either party to any third person or party without the written consent of the other party.
8. The agreement shall be governed by the laws of both India and Venezuela.



IN WITNESS WHEREOF the parties have signed this agreement on the day, month and year indicated above.

SIGNED for and on behalf of SIGNED for and on behalf of

ARVINCARE HEALTH WORLD CASA DE REPRESENTACIONES, C.A



Attested
Minakshi
Minakshi Sharma
Secretary

SALUS PHARMACEUTICALS

SALUS PHARMACEUTICALS
48/271 Villi Haripur, P.O. Gurumajra
Naukarn Road, Baddi-173205
GSTIN: 02AANEL5630E2ZD


SUNVET HEALTHCARE

SUNVET HEALTHCARE
Vill Shambhuwata, Nahani
Peonta Sahib Road, Distt. Simmour (HP)
GSTIN: 02ABZF560121 175



ATTESTED
M. S. SANGWAN
NOTARY PUBLIC
Panchkula, Haryana

Handwritten notes in the top left corner.



ATTESTED

Notary Public, Delhi

भारत सरकार / GOVERNMENT OF INDIA
 अपोस्टिल / APOSTILLE
 (Convention de La Haye du 5 octobre 1961)

Country: **REPUBLIC OF INDIA**

This public document
 COMMERCIAL DOCUMENT
 has been signed by: **MINAKSHI SHARMA**
 acting in the capacity of: **SECRETARY**
 bears the seal/stamp of: **INDO LATIN AMERICAN CHAMBER OF COMMERCE NEW DELHI**

Certified
 at: **NEW DELHI, INDIA** the **15-May-2025**
 by: **SO (O/Attestation) MINISTRY OF EXTERNAL AFFAIRS**
 No: **DLND0006345125**

Seal / Stamp is issued to: **SALUS PHARMACEUTICALS**

Signature

OI 3430164

The Ministry of External Affairs accept no responsibility for the contents of the above documents



(महेन्द्र पाल मीणा)
 (Mahendra Pal Meena)
 अनुभाग अधिकारी (सम्पादन / ओ.आई.)
 Section Officer (Attestation/O.I.)
 सी.पी.डी. प्रभाग / C.P.V. Division
 विदेश मंत्रालय, नई दिल्ली
 Ministry of External Affairs, New Delhi

Supply Agreement between ARVINCARE and HEALTH WORLD CASA DE REPRESENTACIONES, C.A, dated _____

List of products

DESCRIPTION	SPECS	STRENGTH	PHARMACEUTICAL FORM	PRESENTATION
COLISTIMETHATE SODIUM	USP/BP	100mg	LYOPHILIZED POWDER	10 VIAL X BOX
HYDROCORTISONE SODIUM SUCCINATE	USP/BP	100mg	LYOPHILIZED POWDER	10 VIAL X BOX
HYDROCORTISONESODIUMSUCCINATE	USP/BP	500mg	LYOPHILIZED POWDER	10 VIAL X BOX
METHYLPREDNISOLONE SODIUM SUCCINATE	USP/BP	500mg	LYOPHILIZED POWDER	10 VIAL X BOX
MEROPENEM	USP/BP	1gr	LYOPHILIZED POWDER	10 VIAL X BOX
TIGECYCLINE	USP/BP	50mg	LYOPHILIZED POWDER	10 AMPOULE X BOX
AMIKACIN SULPHATE	USP/BP	500mg	INJECTABLE SOLUTION	10 AMPOULE X BOX
TRANEXAMICACID	USP/BP	500mg	INJECTABLE SOLUTION	10 AMPOULE X BOX
IRON SUCROSE	USP/BP	100mg	INJECTABLE SOLUTION	10 AMPOULE X BOX
KETOROLAC TROMETHAMINE	USP/BP	30mg	INJECTABLE SOLUTION	10 VIAL X BOX
ROCURONIUM BROMIDE	USP/BP	50mg	INJECTABLE SOLUTION	10 AMPOULE X BOX
ADRENALINE	USP/BP	1mg/ml	INJECTABLE SOLUTION	10 AMPOULE X BOX
BETAMETASONA FOSFATO/BETAMETASONA	USP/BP	4mg-3mg/ml	INJECTABLE SUSPENSION	10 AMPOULE X BOX
ACETATO	USP/BP	400mg	INJECTABLE SOLUTION	10 AMPOULE X BOX
MOXIFLOXACIN	USP/BP	4mg/2ml	INJECTABLE SOLUTION	10 AMPOULE X BOX
THIOLCHICOSIDE	USP/BP			



07 APR 2025



DICLOFENAC POTASSIUM	USP/BP	50mg/2ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
METRONIDAZOLE	USP/BP	500mg/100ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
DEXAMETHASONE	USP/BP	8mg/2ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
METOCLOPRAMIDE	USP/BP	10mg/2ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
RANITIDINE	USP/BP	50mg/2ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
N-METHYL HYOSCINE BROMIDE	USP/BP	20mg/ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
N-METHYL HYOSCINE BROMIDE-METAMIZOLE	USP/BP	20mg-2.5mg/5ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
METAMIZOLE SODIUM	USP/BP	2.5mg/5ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
ONDASETRON IV	USP/BP	8mg/4ml	INJECTABLE SOLUTION	10 AMPPOULE X BOX
KETOPROFEN	USP/BP	100mg/2ml	DRY POWDER ORAL SUSPENSION	1 BOTTLE X BOX
AMOXICILIN	USP/BP	250MG/5ML	ORAL SUSPENSION	1 BOTTLE X BOX
AZITHROMYCIN	USP/BP	200mg/5ml	DRY POWDER ORAL SUSPENSION	1 BOTTLE X BOX
AMOXICILIN-CLAVULANIC ACID	USP/BP	400mg-57mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX
BROMHEXINE	USP/BP	4mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX
BROMHEXINE	USP/BP	8mg/5ml	ORAL SUSPENSION	1 BOTTLE X BOX
ALBENDAZOLE	USP/BP	400mg/10ml	ORAL SOLUTION	1 BOTTLE X BOX
AMBROXOL HCL	USP/BP	30mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX
AMBROXOL HCL	USP/BP	15mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX
AMBROXOL HCL-LORATADINE	USP/BP	30mg-5mg/5ml	ORAL SUSPENSION	1 BOTTLE X BOX
IBUPROFEN	USP/BP	100mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX
DESLOMATADINE	USP/BP	0.5mg/ml	ORAL SOLUTION	1 BOTTLE X BOX
DEXTROMETORFEN	USP/BP	15mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX
DEXTROMETHORPHAN	USP/BP	7.5mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX

INDO LATIN AMERICAN CHAMBER OF COMMERCE
NEW DELHI, INDIA
14 MAY 2025

07 APR 2025

NOTARY
Abha Tomar
Advocate
New Delhi
Regin. No.
8513
GOVT. OF INDIA

NOTARY PUBLIC
Abha Tomar
Advocate
New Delhi
Regin. No.
8513

CARBOCYSTEINE	USP/BP	250MG/5ML	ORAL SOLUTION	1 BOTTLE X BOX
LORATADINE-BETAMETASONE	USP/BP	1mg-0.05mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX
DICLOFENAC	USP/BP	1.8mg/ml	ORAL SUSPENSION	1 BOTTLE X BOX
CARBAMAZEPINE	USP/BP	2gr/100ml	ORAL SUSPENSION	1 BOTTLE X BOX
PREDNISOLONE	USP/BP	3mg/ml	ORAL SOLUTION	1 BOTTLE X BOX
DEXTROMETORFEN-CLOPPHERAMINE	USP/BP	15mg-3mg/5ml	ORAL SOLUTION	1 BOTTLE X BOX
METRONIDAZOLE	USP/BP	250mg/5ml	OPHTHALMIC SOLUTION	1 BOTTLE X BOX
TOBRAMYCIN-DEXAMETHASONE	USP/BP	0.3%-0.1%	OPHTHALMIC SOLUTION	1 BOTTLE X BOX
DORZOLAMIDE HYDROCHLORIDE/TIMOLOL	USP/BP	2%-0.5%	OPHTHALMIC SOLUTION	1 BOTTLE X BOX
MALÉATE	USP/BP	0.10%	OPHTHALMIC SOLUTION	1 BOTTLE X BOX
DEXTRAN 70	USP/BP	0.30%	OPHTHALMIC SOLUTION	1 BOTTLE X BOX
HYDROXYPROPYLMETHYLCELLULOSE	USP/BP	0.50%	OPHTHALMIC SOLUTION	1 BOTTLE X BOX
CARBOXYMETHYLCELLULOSE	USP/BP		OPHTHALMIC SOLUTION	1 BOTTLE X BOX
SODIUM HYALURONATE	USP/BP	0.03%	OPHTHALMIC SOLUTION	1 BOTTLE X BOX
CIPROFLOXACIN	USP/BP	0.10%	NASAL DROPS	1 BOTTLE X BOX
XYLOMETAZOLINE	USP/BP	0.10%	NASAL DROPS	1 BOTTLE X BOX
NAPHAZOLINE	USP/BP	0.05%	NASAL DROPS	1 BOTTLE X BOX
OXYMETAZOLINE HYDROCHLORIDE	USP/BP	0.01%	NASAL SPRAY	1 BOTTLE X BOX
MOMETASONE FUROATE	USP/BP	0.25mg-0.50mg/ml	NEBULISER SOLUTION	1 BOTTLE X BOX
IPRATOROEM BROMIDE-PHENOTEROL	USP/BP	1mg/ml	NEBULISER SOLUTION	1 BOTTLE X BOX
BUDESONIDE	USP/BP	2.5mg/2.5ml	NEBULISER SOLUTION	1 BOTTLE X BOX
SALBUTAMOL	USP/BP	100mcg/dose	SUSPENSION FOR INHALATION	1 CANISTER X BOX
SALBUTAMOL INHALATION	USP/BP	200mcg/dose	SUSPENSION FOR INHALATION	1 CANISTER X BOX
BUDESONIDE INHALATION	USP/BP			

14 MAY 2025
NEW DELHI, INDIA

NOTARY
Abha Tomar
Advocate
New Delhi
Regn. No.
8513

GOVT. OF INDIA

Regn. No. 8513
OF

CLOTTRIMAZOLE	USP/BP	2%	VAGINAL CREAM	1 TUBE X 7
CLOTTRIMAZOLE	USP/BP	1%	TOPICAL CREAM	1 TUBE X BOX
BETAMETASONE	USP/BP	0.001%	TOPICAL CREAM	1 TUBE X BOX
TOBRAMYCIN-DEXAMETHASONE	USP/BP	0.3%/0.1%	OPHTHALMOLOGIC CREAM	1 TUBE X BOX
METRONIDAZOLE	USP/BP	500mg	OVULE	10 OVULE X BOX
METRONIDAZOLE -MICONAZOLE	USP/BP	15%-4%	VAGINAL CREAM	1 TUBE X 7
METRONIDAZOLE -MICONAZOLE	USP/BP	750mg-200mg	OVULE	APPLICATOR X BOX
METRONIDAZOLE -MICONAZOLE	USP/BP	2%	TOPICAL CREAM	7 OVULE X BOX
KETOCONAZOLE	USP/BP	20mg	GASTRO-RESISTANT CAPSULE	1 TUBE X BOX
OMEPRAZOLE	USP/BP	50mg	COAT TABLET	15 TABLETS X
DICLOFEFNAC POTASSIUM	USP/BP	30mg	ORODISPERSIBLE TABLET	BLISTER X BOX
NIFEDIPINE	USP/BP	500mg	COAT TABLET	10 TABLETS X
AZITHROMYCIN	USP/BP	500mg	COAT TABLET	BLISTER X BOX
CIPROFLOXACIN	USP/BP	500mg	COAT TABLET	03 TABLETS X
NITAZOXANIDE	USP/BP	80mg	COAT TABLET	BLISTER X BOX
VALSARTAN	USP/BP	80mg	COAT TABLET	10 TABLETS X

INDO LAMIN AMERICAN CHAMBER OF COMMERCE
NEW DELHI, INDIA
14 MAY 2025

NOTARY
Abha Tomar
Advocate
New Delhi
Regn. No. 8513
GOVT. OF INDIA

NOTARY PUBLIC
M.S. 37M

0 / APR 2025

IBUPROFEN	USP/BP	800mg	COAT TABLET	10 TABLETS X BLISTER X BOX
FOLIC ACID	USP/BP	10mg	TABLET	10 TABLETS X BLISTER X BOX
RISPERIDONE	USP/BP	2mg	COAT TABLET	10 TABLETS X BLISTER X BOX
DIOSMIN-HISPERIDIN	USP/BP	450mg/50mg	COAT TABLET	10 TABLETS X BLISTER X BOX
VITAMINA E	USP/BP	100mg	SOFT CAPSULE	10 TABLETS X BLISTER X BOX
AMOXICILIN	USP/BP	500mg	CAPSULE	10 TABLETS X BLISTER X BOX
LORATADINE	USP/BP	10mg	TABLET	10 TABLETS X BLISTER X BOX
DESLOTRADINE	USP/BP	5mg	COAT TABLET	10 TABLETS X BLISTER X BOX
PAROXETINE	USP/BP	12.5mg	COAT TABLET	10 TABLETS X BLISTER X BOX
LEVONORGESTREL-ETHINYLESTRADIOL	USP/BP	150mcg/30mcg	COAT TABLET	21 TABLETS X BLISTER X BOX
FLUOXETINE	USP/BP	20mg	CAPSULE	10 TABLETS X BLISTER X BOX
LAMOTRIGINE	USP/BP	50mg	TABLET	10 TABLETS X BLISTER X BOX

INDO LATIN AMERICAN CHAMBER OF COMMERCE
 14 MAY 2025
 NEW DELHI, INDIA

NOTARY
 Abha Tomar
 Advocate
 New Delhi
 Regn. No.
 8513
 GOVT. OF INDIA

0 / APR 2025

NOTARY PUBLIC

INDIA

SIGNED by and on behalf of SIGNED by and on behalf of

ARVINCARE
[Signature]

HEALTH WORLD CASA DE REPRESENTACIONES, C.A



SALUS PHARMACEUTICALS
SALUS PHARMACEUTICALS
480/211 Jharkhand, P.O. Gurumajra
Nalagarh Road, Patna-173205
GSTIN: 02AANFM930E2Z0

SUNVET HEALTHCARE
[Signature]


SUNVET HEALTHCARE
Vill Shambhuvra, Naha
Paonia, Sahib Road, Dist. Sirnoul (HP)
GSTIN: 02ABZTSS012L1729



Attested
Minakshi Sharma
Minakshi Sharma
Secretary

07 APR 2025

34158



Ministry of External Affairs, New Delhi
 Section Officer (Attestation/O.I.)
 (Mahendra Pal Meena)
 (महेंद्र पाल मीना)



This public document
 COMMERCIAL DOCUMENT
 has been signed by
 MINAKSHI SHARMA
 SECRETARY
 acting in the capacity of
 INDO LATIN AMERICAN CHAMBER OF
 COMMERCE NEW DELHI
 at NEW DELHI, INDIA the 15-May-2025
 by SO (OI/Attestation) MINISTRY OF EXTERNAL AFFAIRS
 No DLND0006345225
 Seal / Stamp
 is issued to SALUS PHARMACEUTICALS
 01 3430157

The Ministry of External Affairs
 accept no responsibility for the
 contents of the above documents

Notary Public, Delhi

ATTESTED

7 APR 2025

